Symbols

SGMO

Sangamo Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

High Gross Profit Margin

Significant Revenue Decline

Significant Net Income Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SGMO

Sangamo Therapeutics, Inc.

A leading gene therapy company with a strong pipeline of treatments for rare genetic diseases

Industry

Biological Technology

Established Date

06/22/1995

Listing Date

04/06/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

183

Fiscal Year Ends

12-31

Website

www.sangamo.com

Security Type

Common stock

Office address

501 Canal Blvd., Richmond, California 94804

Business

Introduction

Sangamo Therapeutics, Inc., incorporated in Delaware on June 22, 1995, focuses on the development and commercialization of novel transcription factors for gene regulation and gene modification. The company is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of DNA-binding proteins for new therapeutic strategies for unmet medical needs. Currently, the company's scientific and business development efforts focus on gene regulation and modification of new zinc finger DNA-binding protein engineering. The company's strategy is to develop highly specific zinc finger protein nucleases and zinc finger protein transcription factors through early-stage clinical trials and strategic partnerships with biopharmaceutical companies to perform late-stage clinical trials and commercial development.

Earnings Call

Q1/2025

Estimate EPS-0.13

Actual EPS-0.14

Estimate Revenue7.42M

Actual Revenue6.44M

Sangamo's Q1 2025: Unpacking Contradictions in Fabry Disease Partnerships and Data Transparency

May 20,2025 06:50·
Earnings Decrypt

Company Financials

EPS

SGMO has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.1, missing expectations. The chart below visualizes how SGMO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SGMO has released its 2025 Q3 earnings report, with revenue of 581.00K, reflecting a YoY change of -98.82%, and net profit of -34.93M, showing a YoY change of -427.31%. The Sankey diagram below clearly presents SGMO's revenue sources and cost distribution.